ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best strong buy stocks to invest in under $20. ImmunityBio Inc. (NASDAQ:IBRX) announced on March 20 that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China granted regulatory approval for ANKTIVA®. Management stated that the approval establishes ANKTIVA’s initial presence in Asia, while highlighting ImmunityBio Inc.’s (NASDAQ:IBRX) strategy for the expansion of global access through reliance-based regulatory pathways.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

The company further reported that ANKTIVA gained approval in combination with Bacillus Calmette-Guérin in Macau, for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ ± papillary tumors, which is consistent with its approved use in the United States. It also stated that the authorization was granted after a review considering previous regulatory decisions by the U.S. Food and Drug Administration and the European Medicines Agency, in accordance with applicable local requirements.

Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio Inc. (NASDAQ:IBRX), stated that the approval in Macau highlights the “strength of the clinical and regulatory foundation supporting ANKTIVA in BCG-unresponsive NMIBC CIS, with or without papillary tumors”.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.